Acquired myasthenia gravis
- PMID: 9227954
- DOI: 10.1016/s0733-8619(05)70335-2
Acquired myasthenia gravis
Abstract
Myasthenia gravis, an antibody-mediated disorder of neuromuscular transmission that produces clinical weakness, may be ocular or generalized. Clinical diagnostic evaluation may be supplemented by electrophysiologic studies and antibody testing. Therapeutic options, including anticholinesterase inhibitors, immunosuppressive agents, plasmapheresis and thymectomy, are tailored for the individual patient. This article emphasizes the key aspects of the clinical evaluation, diagnosis, and therapy.
Similar articles
-
Overview of myasthenia gravis.Hosp Pract (1995). 2013 Oct-Nov;41(4):40-50. doi: 10.3810/hp.2013.10.1079. Hosp Pract (1995). 2013. PMID: 24145588
-
A Neurologist's Perspective on Understanding Myasthenia Gravis: Clinical Perspectives of Etiologic Factors, Diagnosis, and Preoperative Treatment.Thorac Surg Clin. 2019 May;29(2):133-141. doi: 10.1016/j.thorsurg.2018.12.002. Epub 2019 Mar 7. Thorac Surg Clin. 2019. PMID: 30927994 Review.
-
Acetylcholine receptor antibodies in the diagnosis of human and experimental myasthenia gravis.Muscle Nerve. 1978 Sep-Oct;1(5):427-31. doi: 10.1002/mus.880010518. Muscle Nerve. 1978. PMID: 263985
-
Clinical statistics of myasthenia gravis in Japan.Int J Neurol. 1980;14(1):87-99. Int J Neurol. 1980. PMID: 6983511 No abstract available.
-
[Myasthenia gravis associated with thyrotoxicosis].Nihon Rinsho. 2006 May 28;Suppl 1:321-3. Nihon Rinsho. 2006. PMID: 16776155 Review. Japanese. No abstract available.
Cited by
-
Late onset generalized myasthenia gravis presenting with facial weakness and bulbar signs without extraocular muscle involvement.Neurol Sci. 2009 Aug;30(4):343-4. doi: 10.1007/s10072-009-0095-x. Epub 2009 May 30. Neurol Sci. 2009. PMID: 19484183
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical